The anti-PD-1 antibody camrelizumab, in combination with chemotherapy, has become the standard first-line regimen in China for patients with advanced NSCLC without EGFR or ALK genomic tumor aberrations [14, 15]. Here, PDCD1 is linked to non-small cell lung carcinoma.